Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2026-05-05 @ 5:44 PM
Study NCT ID:
NCT00911820
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2009-05-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
09-039
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None